Xperi Corp.
TSRA
NASDAQ44.65
USD
-0.15
- -
Xperi Corp.
TSRA
(NASDAQ)
Recent
price
44.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Xperi Corp (TSRA) develops and licenses technologies that enhance audio, video, connectivity, and user experiences across consumer electronics, connected cars, pay TV, and media platforms; its core offerings include DTS premium audio solutions for TVs, PCs, smartphones, soundbars, and automotive systems; HD Radio digital terrestrial broadcasting approved by the FCC for AM/FM in the U.S.; TiVo software and services such as TiVo Stream 4K streaming devices, personalized content discovery, interactive programming guides, and IPTV streaming; imaging technologies for advanced portrait modes, face detection, and in-cabin monitoring; IMAX Enhanced for cinematic video and sound; edge-based machine learning for security cameras and battery-powered devices; and connected car solutions encompassing automotive connected media and multi-channel video UX. The company operates globally with headquarters in San Jose, California, where it was effectively formed through mergers tracing origins to 1990 with DTS Inc., and maintains offices across North America, Europe, Asia, and Australia, serving consumer electronics manufacturers, automotive OEMs including BMW, Honda, Hyundai, and Volkswagen, pay TV operators, and media platforms. Recent developments include achieving its 2025 goal of expanding TiVo OS TV partnerships to 10 operators with a new European brand for an Asia-based manufacturer in Q3 2025; appointing Matt Milne as President of TiVo Ads in November 2025 to bolster connected TV advertising; signing multi-year HD Radio IC agreements and launching new vehicle models with key partners in H1 2025; and selling its Perceive AI chip unit to Amazon for $80 million in 2024, allowing focus on core entertainment and connectivity technologies.
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)